What do systematic reviews say?

Biofeedback plus standard therapy vs usual care

The review found no eligible studies for this question.

• Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Biofeedback vs relaxation training

The review found no eligible studies for this question.

• Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Biofeedback plus standard therapy vs sham biofeedback plus standard therapy

The review found no eligible studies for this question.

• Biofeedback for treatment of irritable bowel syndrome 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

The intervention showed no clear difference in other serious adverse events (low certainty).

• Percutaneous vertebroplasty for osteoporotic vertebral compression fracture 2018 · Cochrane Headline outcomes only
  RR 0.61 [0.33, 1.1]
  5 studies · 821 participants
  Low

IVIg vs placebo

Intravenous immunoglobulin showed no clear difference in serious adverse events (SAE) compared with placebo (low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 0.73 [0.32, 1.65]
  1 study · 100 participants
  Low

Moxifloxacin vs amoxicillin‐clavulanate

It is very uncertain whether moxifloxacin changes serious adverse events (SAE) compared with amoxicillin‐clavulanate (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 0.63 [0.3, 1.31]
  1 study · 54 participants
  Very low

AB103 vs placebo

It is very uncertain whether AB103 changes serious adverse events (SAE) compared with placebo (very low certainty).

• Interventions for necrotizing soft tissue infections in adults 2018 · Cochrane Headline outcomes only
  RR 1.49 [0.52, 4.27]
  1 study · 43 participants
  Very low

Adverse event outcomes for dietary combined with physical activity interventions vs usual care

• Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications… 2017 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 250 participants
  Low

Imiquimod vs cidofovir

Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).

• Medical and surgical interventions for the treatment of usual‐type vulval intraepithelial neoplasia 2016 · Cochrane Headline outcomes only
  RR 1.26 [0.88, 1.81]
  1 study · 168 participants
  Moderate

Mobile bearing vs fixed bearing prosthesis

Mobile bearing may leads to higher other serious adverse events compared with fixed bearing prosthesis (low certainty).

• Mobile bearing vs fixed bearing prostheses for posterior cruciate retaining total knee arthroplasty for postoperative… 2015 · Cochrane Headline outcomes only
  RR 1.16
  17 studies · 1732 participants
  Low

160/4.5 mcg BDF single inhaler therapy vs current best practice

160/4.5 mcg BDF single inhaler therapy showed no clear difference in fatal serious adverse events compared with current best practice (low certainty).

• Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes only
  OR 1.95 [0.53, 7.21]
  8 studies · 8841 participants
  Low

Single inhaler therapy vs fixed dose ICS

Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).

• Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including… 2013 · Cochrane Headline outcomes only
  OR 0.37 [0.05, 2.62]
  3 studies · 4209 participants
  Moderate

Abatacept (2 and 10mg/kg) + DMARDs/biologic vs placebo + DMARDs/biologic

Abatacept (2 and 10mg/kg) + DMARDs/biologic showed no clear difference in total serious adverse events compared with placebo + DMARDs/biologic (moderate certainty).

• Abatacept for rheumatoid arthritis 2009 · Cochrane Headline outcomes only
  RR 1.05 [0.87, 1.28]
  6 studies · 3151 participants
  Moderate

Fibrin‐based haemostatic agents vs placebo or no intervention

It is very uncertain whether fibrin‐based haemostatic agents changes serious adverse events Median compared with no intervention or placebo (very low certainty).

• Fibrin‐based haemostatic agents for reducing blood loss in adult liver resection 2023 · Cochrane Headline outcomes only
  RR 0.96 [0.88, 1.05]
  4 studies · 782 participants
  Very low

Fibrin‐based haemostatic agents vs non‐fibrin‐based haemostatic agents

Fibrin‐based haemostatic agents showed no clear difference in serious adverse events Median compared with non‐fibrin‐based haemostatic agents (low certainty).

• Fibrin‐based haemostatic agents for reducing blood loss in adult liver resection 2023 · Cochrane Headline outcomes only
  RR 0.99 [0.95, 1.03]
  9 studies · 1176 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Normothermic machine perfusion (NMP) vs static cold storage (SCS)

• Machine perfusion in liver transplantation 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 522 participants
  GRADE not reported

Hysterectomy (simple or radical) with radiotherapy vs Radiotherapy alone

Hysterectomy (simple or radical) with radiotherapy may leads to higher severe/serious adverse events compared with radiotherapy alone (low certainty).

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  OR 4
  2 studies · 374 participants
  Low

Hysterectomy (simple or radical) with chemoradiotherapy vs chemoradiotherapy alone

The review found no eligible studies for this question.

• Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Discontinuing cholinesterase inhibitor vs continued cholinesterase inhibitor

Discontinuing cholinesterase inhibitor showed no clear difference in serious adverse events (SAEs) compared with continued cholinesterase inhibitor (low certainty).

• Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia 2021 · Cochrane Headline outcomes only
  OR 0.8 [0.46, 1.39]
  4 studies · 390 participants
  Low